Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”
A. M. Lila,
V. I. Mazurov,
E. L. Nasonov,
S. A. Lukyanov,
T. V. Dubinina,
I. Z. Gaidukova,
A. A. Klimenko,
S. A. Lapshina,
G. V. Lukina,
M. A. Korolev,
R. O. Dreval,
P. I. Pchelnikova,
N. V. Shatalova https://doi.org/10.14412/1996-7012-2024-3-134-139
Abstract
On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.
Supporting agencies: The paper has been sponsored by BIOCAD
About the Authors
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
115522; 34A, Kashirskoe Shosse; 125993; 2/1, Barrikadnaya Street, Build. 1; Moscow
V. I. Mazurov
North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia
Russian Federation
Russian Federation
191015; 41, Kirochnaya Street; St. Petersburg
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
115522; 34A, Kashirskoe Shosse; 119991; 8, Trubetskaya Street, Build. 2; Moscow
S. A. Lukyanov
Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
117997; 1, Ostrovitianov Street; Moscow
T. V. Dubinina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Tatyana Vasilievna Dubinina
115522; 34A, Kashirskoe Shosse; Moscow
I. Z. Gaidukova
North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia; Clinical Rheumatological Hospital № 25
Russian Federation
Russian Federation
191015; 41, Kirochnaya Street; 190068; 30A, Bolshya Podyacheskaya Street; St. Petersburg
A. A. Klimenko
Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
117997; 1, Ostrovitianov Street; Moscow
S. A. Lapshina
Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
420012; 49, Butlerov Street; Kazan
G. V. Lukina
V.A. Nasonova Research Institute of Rheumatology; A.S. Loginov Moscow Clinical Scientific and Practical Center
Russian Federation
Russian Federation
115522; 34A, Kashirskoe Shosse; 111123; 86, Entuziastov Shosse,Build. 6; Moscow
M. A. Korolev
Institute of Clinical and Experimental Lymphology – branch of the Institute of Cytology and Genetics SB RAS
Russian Federation
Russian Federation
630060; 2, Timakov Street; Novosibirsk
R. O. Dreval
Center for Social Economics
Russian Federation
Russian Federation
119421; 111, Leninskiy Prospect, Build. 1; Moscow
P. I. Pchelnikova
Russian Union Of Patients Public Societies; All-Russian Non-profit Organization of disabled people “Russian
Rheumatological Association “Nadezhda”
Russian Federation
Russian Federation
125167; 5, Naryshkinskaya Avenue, Build. 2; 115516; 11, Promyshlennaya Street, Build. 3; Moscow
N. V. Shatalova
Interregional public charity organization for people with disabilities “Mutual Aid Society for Bekhterev’s Disease”
Russian Federation
Russian Federation
107078; 9/2-4, Novaya Basmannaya Street, Build. 6; Moscow
References
1. Britanova OV, Lupyr KR, Staroverov DB, et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023 Nov;29(11):2731-2736. doi: 10.1038/s41591-023-02613-z. Epub 2023 Oct 23.
2. Gaidukova IZ, Mazurov VI. The pathogenesis of axial spondyloarthritis as the basis of treatment — realities and prospects. Russkii meditsinskii zhurnal. 2023;(7):6-14. (In Russ.)
3. Decision of the Council of the Eurasian Economic Commission dated 03. 11. 2016 № 78 (as amended on 10/20/2023) "On the Rules for registration and examination of medicines for medical use" https://docs.eaeunion.org/docs/ru-ru/01411969/cncd_21112016_78
4. General characteristics of the medicinal product (GCMP) seniprutug https://lk.regmed.ru/register/EAEU_SmPC
5. Nasonov EL, Mazurov VI, Lila AM, et al. Efficacy and safety of BCD-180, a monoclonal antibody to TRBV9+ T lymphocytes, in patients with active radiological axial spondyloarthritis: results of a 36-week randomized double-blind placebo-controlled phase 2 clinical trial of ELEFTA. Nauchno-prakticheskaya revmatologiya. 2024;62(1):65–80. (In Russ.)
6. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
7. Izrael'son MA, Stepanov AV, Staroverov DB, et al. Testing of monoclonal antibodies to the T-cell receptor associated with ankylosing spondylitis. Vestnik RGMU. 2018;(5):83-92. (In Russ.)
8. Lila AM, Dubinina TV, Tolkacheva DG, et al. Comparative analysis of the efficacy of seniprutug (BCD-180) and adalimumab in the treatment of active radiographic axial spondyloarthritis : results of a systematic review and matching-adjusted indirect comparison. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2024;18(2):33–40. (In Russ.). doi: 10.14412/1996-7012-2024-2-33-40.
Review
For citations:
Lila AM, Mazurov VI, Nasonov EL, Lukyanov SA, Dubinina TV, Gaidukova IZ, Klimenko AA, Lapshina SA, Lukina GV, Korolev MA, Dreval RO, Pchelnikova PI, Shatalova NV. Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(3):134-139. (In Russ.) https://doi.org/10.14412/1996-7012-2024-3-134-139
Views:
1066
Email this article 